Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China

about

Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China

Item

http://www.wikidata.org/entity/Q58800689

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Cost-effectiveness analysis of ...... atocellular carcinoma in China

@en

Cost-effectiveness analysis of ...... atocellular carcinoma in China

@nl

type

Item

label

Cost-effectiveness analysis of ...... atocellular carcinoma in China

@en

Cost-effectiveness analysis of ...... atocellular carcinoma in China

@nl

prefLabel

Cost-effectiveness analysis of ...... atocellular carcinoma in China

@en

Cost-effectiveness analysis of ...... atocellular carcinoma in China

@nl

P1476

Cost-effectiveness analysis of ...... atocellular carcinoma in China

@en

P2093

Eliza Kruger

http://www.w3.org/2001/XMLSchema#string

Jun Liang

http://www.w3.org/2001/XMLSchema#string

Nanya Wang

http://www.w3.org/2001/XMLSchema#string

Seng Chuen Tan

http://www.w3.org/2001/XMLSchema#string

Shukui Qin

http://www.w3.org/2001/XMLSchema#string

Shuqun Cheng

http://www.w3.org/2001/XMLSchema#string

P2860

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Management of hepatocellular carcinoma

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

Using economic evaluation in policy decision-making in Asian countries: mission impossible or mission probable?

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.

Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.

Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.

P2888

s12962-018-0112-0

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12962-018-0112-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1105975843

http://www.w3.org/2001/XMLSchema#string

P698

30087583

http://www.w3.org/2001/XMLSchema#string

P921

health policy

P932

6076412

http://www.w3.org/2001/XMLSchema#string